12 News & Press Releases found
Inflammatix, Inc. News
-
Inflammatix Appoints Dr. Kian Beyzavi as New Board Member
Inflammatix, a pioneering molecular diagnostics company, announced today the appointment of Kian Beyzavi, PhD, as an independent member of the company’s board of directors. Dr. Beyzavi is a seasoned veteran of the healthcare industry with ...
-
Inflammatix Announces Additional $12.1 Million Funding from BARDA for ViraBac EZ Acute Infection Test
Inflammatix, a pioneering molecular diagnostics company, announced today a contract extension of $12.1 million from the Biomedical Advanced Research and Development Authority (BARDA), part of the U.S. Department of Health and Human Services’ ...
-
Inflammatix Awarded $1.7 Million Grant From National Institutes of Health (NIH)
Inflammatix, a pioneering molecular diagnostics company, announced today that the National Institute of General Medical Sciences, part of the National Institutes of Health, has awarded the company a Small Business Innovation Research (NIH SBIR) ...
-
Inflammatix Appoints Amy Boyle as Chief Operating Officer
Inflammatix, a pioneering molecular diagnostics company, announced today the appointment of experienced medical device executive Amy Boyle as Chief Operating Officer, effective April 5, 2021. Ms. Boyle brings 30 years of broad commercial medical ...
-
Inflammatix Secures $102 Million in Series D Financing Led by D1 Capital Partners to Commercialize Novel Host Response Diagnostics
Inflammatix, a pioneering molecular diagnostics company, announced today the closing of a $102 million Series D round of financing to support development and commercialization of its novel immune response diagnostics portfolio. D1 Capital Partners ...
-
Inflammatix Announces $7.4 Million in Additional BARDA Funding to Advance ViraBac EZ Acute Infection Test
Inflammatix a pioneering molecular diagnostics company, announced today a contract extension of $7.4 million from the Biomedical Advanced Research and Development Authority (BARDA), part of the U.S. Department of Health and Human ...
-
DARPA Awards Inflammatix up to $1.1 Million to Develop Diagnostic that Predicts COVID-19 Severity Risk
Inflammatix a pioneering molecular diagnostics company, announced today that the Defense Advanced Research Projects Agency (DARPA) has awarded the company up to $1.1 million for further development of a rapid diagnostic that reads the immune ...
-
Study Demonstrates Substantial Cost Savings in Health Economic Model of the Inflammatix Host-Response Test for Sepsis
Inflammatix, a pioneering molecular diagnostics company delivering precision medicine at the point of care, announced the publication of a health economic model that shows use of the company’s HostDxTM Sepsis test in patients suspected of ...
-
Inflammatix Appoints João Fonseca, Ph.D., as Chief Technology Officer
Inflammatix, a pioneering molecular diagnostics company delivering precision medicine at the point of care, today announced the appointment of João Fonseca, Ph.D., as Chief Technology Officer. Dr. Fonseca will oversee Inflammatix’s ...
-
Leading Stanford Alumni Scientists and Physicians Launch StartX Med COVID-19 Task Force
70+ StartX Med Innovators with Medical Breakthroughs for the Prevention, Diagnostics and Treatment of Coronavirus Mobilize Efforts to Fast-Track Public Health Needs During Pandemic. StartX, a non-profit startup community of more than ...
-
New Inflammatix Study in Nature Communications Outlines Breakthrough in Diagnosing Acute Infections by Reading the Immune System
Inflammatix, a pioneering molecular diagnostics company delivering precision medicine at the point of care, announced findings from a new study published today in Nature Communications that demonstrate its ability to identify patients with bacterial ...
-
Inflammatix Announces $32 Million in Series C Funding
Financing will be used to advance HostDx tests for acute infections and sepsis to commercial launch in 2021. Inflammatix, a pioneering molecular diagnostics company delivering precision medicine at the point of care, today announced a $32 ...